While 58 (43%) cases of breast carcinoma biopsies with incomplete response or no response to neo-adjuvant therapy have shown moderate (Fig. 6e) to high (Fig. 6g) expression of TFF3 in pre-neoadjuvant biopsies and post neoadjuvant biopsies (Fig. 6f and h). The gene discussed is TFF3; the disease is breast carcinoma.